Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection

• Published in: Acta ophthalmologica (Oxford, England) Vol. 91; no. 4; pp. e304 - e310
• Main Authors: Xu, Yu, Zhang, Qi, Kang, Xiaoli, Zhu, Ying, Li, Jiakai, Chen, Yiye, Zhao, Peiquan
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.06.2013; Wiley Subscription Services, Inc
• Subjects: Angiogenesis Inhibitors - administration & dosage; Antibodies, Monoclonal, Humanized - administration & dosage; Bevacizumab; Birth Weight; Dose-Response Relationship, Drug; Eye surgery; Female; Follow-Up Studies; Gestational Age; Humans; Infant, Newborn; Intravitreal Injections; lens‐sparing vitrectomy; Male; Medical research; neovascularization; Ophthalmology; Preoperative Care - methods; Retinal Neovascularization - etiology; Retinal Neovascularization - pathology; Retinal Neovascularization - prevention & control; Retinal Vessels - pathology; retinopathy of prematurity; Retinopathy of Prematurity - complications; Retinopathy of Prematurity - pathology; Retinopathy of Prematurity - therapy; Retrospective Studies; Surgery; Surgical outcomes; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity; Vitrectomy
• ISSN: 1755-375X; 1755-3768
• DOI: 10.1111/aos.12055

. Purpose:  To evaluate the effect of early vitreoretinal surgery on vascularly active stage 4 ROP through the preoperative use of intravitreal bevacizumab. Methods:  This was a retrospective study. Eighteen patients with vascularly active stage 4 ROP who underwent primary vitrectomy from April 2007 to March 2010 were enrolled. Twelve eyes from eight patients received one‐time intravitreal injection of 0.625 mg bevacizumab 7 days prior to vitrectomy (bevacizumab group), and 11 eyes from 10 patients underwent the surgical procedure without bevacizumab (control group). Demographical information of all patients was recorded. The patients were followed up for 12–36 months after the surgery. The postmenstrual age at vitrectomy, surgical procedure, anatomical and visual outcome, adverse effects and surgical complications were compared. Results:  There was no statistically significant difference between the two groups in gender, birthweight and gestational age. The bevacizumab group showed remarkable regression of vascular activity after the injection. The mean postmenstrual age at the time of vitrectomy was significantly earlier in the bevacizumab group (40 versus 47 weeks, p = 0.002) compared with the controls. The mean surgery time was shorter in the bevacizumab group (74.81 versus 101.70 min, bevacizumab group versus control, p = 0.002). At the final follow‐up, all patients in the bevacizumab group achieved anatomical retinal attachment, compared with 70% in the control group. Eighty‐eight per cent patients in the bevacizumab group obtained pattern vision, while it was 30% in the control group (p = 0.015). Conclusion:  Intravitreal bevacizumab administrated prior to vitrectomy effectively reduced active neovascularization in vascularly active stage 4 ROP patients, thus advancing the timing of vitrectomy and facilitating pars plicata vitrectomy (PPV).